Publications by authors named "Eva Haspinger"

Claim this Profile
A
Author Correction: Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer.
Alessandra Fabi, Luisa Carbognin, Andrea Botticelli, Ida Paris, Paola Fuso, Eva Regina Haspinger

NPJ Breast Cancer· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer.
Alessandra Fabi, Luisa Carbognin, Andrea Botticelli, Ida Paris, Paolo Fuso, Eva Regina Haspinger

NPJ Breast Cancer· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer.
Alessandra Fabi, Luisa Carbognin, Andrea Botticelli, Ida Paris, Paola Fuso, Eva Regina Haspinger

NPJ Breast Cancer· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimizing CDK4/6 inhibitors in advanced HR+/HER2- breast cancer: A personalized approach.
Caterina Fontanella, Carlo Alberto Giorgi, Stefania Russo, Silvia Angelini, Linda Nicolardi, Eva R Haspinger

Crit Rev Oncol Hematol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Infection rate and clinical management of cancer patients during the COVID-19 pandemic: experience from a tertiary care hospital in northern Italy.
Dominic Fong, Simon Rauch, Christian Petter, Eva Haspinger, Monika Alber

ESMO Open· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic value of histogram analysis in advanced non-small cell lung cancer: a radiomic study.
Bluthgen Maria Virginia, Faivre Laura, Rosellini Silvia, Ferrara Roberto, Facchinetti Francesco, Haspinger Eva

Oncotarget· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Limits of radiomic-based entropy as a surrogate of tumor heterogeneity: ROI-area, acquisition protocol and tissue site exert substantial influence.
Laurent Dercle, Samy Ammari, Mathilde Bateson, Paul Blanc Durand, Eva Haspinger

Sci Rep· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Is there evidence for different effects among EGFR-TKIs? Systematic review and meta-analysis of EGFR tyrosine kinase inhibitors (TKIs) versus chemotherapy as first-line treatment for patients harboring EGFR mutations.
Eva Regina Haspinger, Francesco Agustoni, Valter Torri, Francesco Gelsomino, Marco Platania

Crit Rev Oncol Hematol· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fatal case of hepatic portal venous gas following palliative stenting and chemotherapy for occlusive advanced colorectal cancer.
Marco Platania, Barbara Valeri, Alfonso Marchianò, Giuseppina Calareso, Francesco Agustoni, Eva Haspinger

Int J Colorectal Dis· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activity of the EGFR-HER2 dual inhibitor afatinib in EGFR-mutant lung cancer patients with acquired resistance to reversible EGFR tyrosine kinase inhibitors.
Lorenza Landi, Marcello Tiseo, Rita Chiari, Serena Ricciardi, Elisa Rossi, Eva Regina Haspinger

Clin Lung Cancer· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Does immunohistochemistry affect response to therapy and survival of inoperable non-small cell lung carcinoma patients? A survey of 145 stage III-IV consecutive cases.
Giuseppe Pelosi, Eva Regina Haspinger, Manuela Bimbatti, Giorgia Leone, Biagio Paolini

Int J Surg Pathol· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Do we really need another epidermal growth factor receptor tyrosine kinase inhibitor in first-line treatment for patients with non-small-cell lung cancer and EGFR mutations?
Eva R Haspinger, Marina Chiara Garassino, Valter Torri, Michela Cinquini, Filippo De Braud

J Clin Oncol· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Emerging toxicities in the treatment of non-small cell lung cancer: ocular disorders.
Francesco Agustoni, Marco Platania, Milena Vitali, Nicoletta Zilembo, Eva Haspinger

Cancer Treat Rev· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Epidermal growth factor receptor tyrosine kinase inhibitor treatment in patients with EGFR wild-type non-small-cell lung cancer: the never-ending story.
Francesco Gelsomino, Francesco Agustoni, Monica Niger, Marika Valota, Eva R Haspinger

J Clin Oncol· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metformin inhibits leptin-induced growth and migration of glioblastoma cells.
Rita Ferla, Eva Haspinger, Eva Surmacz

Oncol Lett· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and development of a peptide-based adiponectin receptor agonist for cancer treatment.
Laszlo Otvos, Eva Haspinger, Francesca La Russa, Federica Maspero, Patrizia Graziano

BMC Biotechnol· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis